Retatrutide ZPHC — 20 mg (5 vials × 4 mg)

Retatrutide — dual GLP-1 / GIP receptor agonist
5 lyophilised vials × 4 mg (total 20 mg)

• Dual-incretin synergy: simultaneous GLP-1 & GIP activation delivers superior appetite suppression, enhanced insulin sensitivity and accelerated fat-loss.
• Once-weekly research dosing: long half-life allows a single sub-Q dose per week.
• Reconstitution: add 2 ml bacteriostatic water → 2 mg/ml; swirl gently, avoid foaming. Store 2 – 8 °C.
• Titration guide (research): Week 1-4 → 0.5 mg • Week 5-8 → 1 mg • escalate to 2.5 mg weekly if well-tolerated. Increase gradually to minimise GI effects.
• Pharma-grade QC: ≥ 99 % purity, endotoxin < 0.03 EU/mg; each box bears a scratch-code for authenticity.
• Cold-chain packed • tamper-evident vials • discreet, tracked worldwide delivery.